COVID Clinical Trial
Official title:
The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19
Filter facepiece respirator (FFR) is a critical equipment to prevent the transmission of
respiratory tract infection disease especially the dreadful corona virus 2(SARs-CoV-2).The
N95 mask is the prototype of high efficiency protective device and can effectively protect
airborne pathogens of less than 0.3 μm by more than 95%. It is tightly fit and had high
filtration capacity. The widespread pandemic of COVID-19 leads to greater requirement of FFR.
A rising in demand would greatly exceed current productive capabilities and stockpiles and
would almost certainly result in a robust shortage.
In order to solve these problems, our team had invented a new type of half-piece respirator
made from silicone and assembled with hepa or elastostatic filter . A variety of methods have
been used to evaluate this new device, including qualitative fit test with Bitrex® test kit
and filtration test.
As required by Occupational Safety and Health Administration OSHA)[7], the halfpiece
respirators need to pass the fittestto identify those individuals who do not achieve the good
fit necessary for adequate protection. The performance of this respirator was also determined
by measuring percent leakage under constant airflow[8]. The purposes of this study was to
evaluate the fitting characteristicof our newly invented silicone N99 respirator and the
performance against 30 µm particles using NaCL aerosols. The study was conducted to achieve
two specific research objectives
1. To investigate the fit characteristic of the novel silicone mask and whether the strap
adjustment can help reduce the face-seal leakage
2. To determine the level of performance by measure the inward leakage of the generated
aerosolswith the new filter and used filter for up to 24 hours.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04420676 -
Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection
|
N/A | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Completed |
NCT04425317 -
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
|
N/A | |
Completed |
NCT04395911 -
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections
|
N/A | |
Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
Completed |
NCT04425720 -
Use of Remote Monitoring for COVID-19 Patient
|
N/A | |
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Completed |
NCT04419610 -
RAS and Coagulopathy in COVID19
|
Early Phase 1 | |
Completed |
NCT04546581 -
Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)
|
Phase 3 | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Not yet recruiting |
NCT04524156 -
COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2
|
N/A | |
Completed |
NCT04441710 -
Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
|
||
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT04392427 -
New Antiviral Drugs for Treatment of COVID-19
|
Phase 3 | |
Terminated |
NCT04614025 -
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
|
Phase 2 | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 |